The Leader Manufacturer of  Powder-TGY Bioteach

Quick details of Liraglutide

1.Production Description of Liraglutide

Liraglutide (NN2211) is a long-acting glucagon-like peptide-1 receptor agonist, binding to the same receptors as does the endogenous metabolic hormone

GLP-1 that stimulates insulin secretion. Marketed under the brand name Victoza, it is developed by Novo Nordisk for the treatment oftype 2 diabetes. In 2015, Novo Nordisk began marketing it in the U.S. and E.U. under the brand name Saxenda
as a treatment for adults, who are obese or overweight with at least one weight-relatedcomorbid condition.

Liraglutide is a long-acting glucagon-like peptide-1 receptor agonist, binding to the same receptors as does the endogenous metabolic hormone GLP-1 that stimulates insulin secretion. 

2..Specification of Liraglutide

Don't hesitate to contact us for latest COA and Test Report of Liraglutide

1.Liraglutide acts in a glucose-dependent manner, meaning it will stimulate insulin secretion only when blood glucose levels are higher than normal, preventing "overshoot". Consequently, it shows negligible risk of hypoglycemia.

2.Liraglutide has the potential for inhibiting apoptosis and stimulating regeneration of beta cells (seen in animal studies).

3.Liraglutide decreases appetite and inhibits body weight gain, as shown in a head-to-head study glimepiride.

4.Liraglutide lowers blood triglyceride levels.

Liraglutide has been approved as an injectable adjunct to a reduced-calorie diet and increased physical activity for chronic
weight management in adult patients. The specified criteria are an initial body mass index (BMI) of 30 kg/m2 or greater (obese),
or 27 kg/m2 or greater (overweight), in the presence of at least one weight-related comorbid condition (e.g.hypertension, type 2 diabetes mellitus, or dyslipidemia). In late 2014, data were reported from the SCALE™ Obesity and Prediabetes trial, which is a randomised, double-blind, placebo-controlled, multinational trial in non-diabetic people with obesity and non-diabetic people who are overweight with comorbidities. In this phase 3a trial, there were 3,731 participants randomised to treatment with liraglutide 3 mg or placebo, both in combination with diet and exercise. Those who completed the 56-week trial achieved an average weight loss of 9.2%, to be compared with a 3.5% reduction in the placebo group.


QUALITY IS OUR CULTURE

It's our purpose to provide better service.

It's our responsibility to guarantee the quality of products. 

It's our pursuit target to develop together with our clients. 






Xi'an Tian Guangyuan Biotech Co., Ltd.

Sophie Lee/Sales Manager

 

Web:tgybio.en.made-in-china.com




XIAN Tian Guangyuan Biotech Co.,Ltd.Was founded in May 2003, is a professional animal and plant Extracts
modernand advanced enterprise object, chemical intermediates and active ingredients of Natural active
throughout the country,plant extracts industry, research and development, production,Marketing and other
areas have a strong strength.The company is headquartered in the outskirts of Xi'an, under research and
development center as well as analysisand testing center, comprehensive strength in the national forefront
of the industry.Companies rely on the wisdom andinnovation of advanced technology, scientific management
and all the staff and a good team spirit, will enable the companyto develop a domestic industry with sik-class
product quality and international competitiveness of enterprises.